Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CT55 Biologics Sequence Review Report 2026: Cancer/testis antigen 55 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CT55 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CT45A1 Biologics Sequence Review Report 2026: Cancer/testis antigen family 45 member A1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CT45A1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CRHR2 Biologics Sequence Review Report 2026: Corticotropin-releasing hormone receptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CRHR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CR1 Biologics Sequence Review Report 2026: Complement receptor type 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CMKLR1 Biologics Sequence Review Report 2026: Chemerin-like receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CMKLR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CLNK Biologics Sequence Review Report 2026: Cytokine-dependent hematopoietic cell linker Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CLNK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CLCF1 Biologics Sequence Review Report 2026: Cardiotrophin-like cytokine factor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CLCF1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CKLF Biologics Sequence Review Report 2026: Chemokine-like factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CKLF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CISH Biologics Sequence Review Report 2026: Cytokine-inducible SH2-containing protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CISH sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CIB4 Biologics Sequence Review Report 2026: Calcium and integrin-binding family member 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CIB4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CIB3 Biologics Sequence Review Report 2026: Calcium and integrin-binding family member 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CIB3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CIB2 Biologics Sequence Review Report 2026: Calcium and integrin-binding family member 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CIB2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.